|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | An App knock-in rat model for Alzheimer’s disease exhibiting Aβand tau pathologies,neuronal death and cognitive impairments显示文摘A major obstacle in Alzheimer’s disease(AD)research is the lack of predictive and translatable animal models that reflect disease progression and drug efficacy.Transgenic mice overexpressing amyloid precursor protein(App)gene manifest non-physiological and ectopic expression of APP and its fragments in the brain,which is not observed in AD patients.The App knock-in mice circumvented some of these problems,but they do not exhibit tau pathology and neuronal death.We have generated a rat model,with three familiar App mutations and humanized Aβsequence knocked into the rat App gene.Without altering the levels of full-length APP and other APP fragments,this model exhibits pathologies and disease progression resembling those in human patients:deposit of Aβplaques in relevant brain regions,microglia activation and gliosis,progressive synaptic degeneration and AD-relevant cognitive deficits.Interestingly,we have observed tau pathology,neuronal apoptosis and necroptosis and brain atrophy,phenotypes rarely seen in other APP models.This App knock-in rat model may serve as a useful tool for AD research,identifying new drug targets and biomarkers,and testing therapeutics. | Keliang Pang Richeng Jiang Wei Zhang Zhengyi Yang Lin-Lin Li Makoto Shimozawa Simone Tambaro Johanna Mayer Baogui Zhang Man Li Jiesi Wang Hang Liu Ailing Yang Xi Chen Jiazheng Liu Bengt Winblad Hua Han Tianzi Jiang Weiwen Wang Per Nilsson Wei Guo Bai Lu | 2022 | Cell Research2022，32，2： | 6 |
| 2 | Ovarian cancer standard of care: are there real alternatives?显示文摘Ovarian cancer remains a major issue for gynecological oncologists, and most patients are diagnosed when the disease is already advanced with a poor chance of survival. Debulking surgery followed by platinum-taxane chemotherapy is the current standard of care, but based on several different strategies currently under evaluation, some encouraging data have been published in the last 4 to 5 years. This review provides a state-of-the-art overview of the available alternatives to conventional treatment and the most promising new combinations. For example, neoadjuvant chemotherapy does not seem to be inferior to primary debulking. Despite its outcome improvements, intraperitoneal chemotherapy struggles for acceptance due to the heavy toxicity. Dose-dense chemotherapy, after showing an impressive efficacy in Asian populations, has not produced equal results in a European cohort, and the results of alternative platinum doublets are not superior to those of carboplatin and paclitaxel. In this setting, adherence to a maintenance therapy after first-line treatment and multiple(primarily antiangiogenic) agents appears to be effective. Although many questions, including the duration of maintenance treatment and the use of bevacizumab beyond progression, remain unanswered, new biologic agents, such as poly(ADP-ribose) polymerase(PARP) inhibitors, nintedanib, and mitogen-activated protein/extracellular signal-regulated kinase(MEK) inhibitors, have emerged as potential therapeutic options in the very near future. Based on the multiplicity of available strategies, the histological and molecular features of the tumor, in addition to patient's clinical condition and disease state, continue to gain importance in guiding treatment choices. | Chiara Della Pepa Giuseppe Tonini Carmela Pisano Marilena Di Napoli Sabrina Chiara Cecere Rosa Tambaro Gaetano Facchini Sando Pignata | 2015 | Chinese Journal of Cancer2015，34，1： | 5 |
| 3 | Vertical hepatitis C virus transmission:Main questions and answers显示文摘Hepatitis C virus(HCV) affects about 3% of the world's population and peaks in subjects aged over 40 years. Its prevalence in pregnant women is low(1%-2%) in most western countries but drastically increases in women in developing countries or with high risk behav-iors for blood-transmitted infections. Here we review clinical, prognostic and therapeutic aspects of HCV in-fection in pregnant women and their offspring infected through vertical transmission. Pregnancy-related im-mune weakness does not seem to affect the course of acute hepatitis C but can affect the progression of chronic hepatitis C. In fact, postpartum immune res-toration can exacerbate hepatic inflammation, thereby worsening the liver disease, particularly in patients with liver cirrhosis. HCV infection increases the risk of gestational diabetes in patients with excessive weight gain, premature rupture of membrane and caesarean delivery. Only 3%-5% of infants born to HCV-positive mothers have been infected by intrauterine or perinatal transmission. Maternal viral load, human immunode-ficiency virus coinfection, prolonged rupture of mem-branes, fetal exposure to maternal infected blood con-sequent to vaginal or perineal lacerations and invasive monitoring of fetus increase the risk of viral transmis-sion. Cesarean delivery and breastfeeding increases the transmission risk in HCV/human immunodeficiency virus coinfected women. The consensus is not to offer antivi-ral therapy to HCV-infected pregnant women because it is based on ribavirin(pregnancy category X) because of its embryocidal and teratogenic effects in animal spe-cies. In vertically infected children, chronic C hepatitis is often associated with minimal or mild liver disease and progression to liver cirrhosis and hepatocarcinoma is lower than in adults. Infected children may be treated after the second year of life, given the adverse effects of current antiviral agents. | Grazia Tosone Alberto Enrico Maraolo Silvia Mascolo Giulia Palmiero Orsola Tambaro Raffaele Orlando | 2014 | World Journal of Hepatology2014，6，8： | 5 |
| 4 | Histone acetyltransferase inhibitors and preclinical studies显示文摘 | Manzo F Tambaro FP MaiA | 2009 | Expert Opin Ther Pat2009，19，： | 1 |
| 5 | Aetivity of ehemotherapy in mueinous epithelial ovarian eaneer:A retrospective study显示文摘 | Pisano C Greggi S Tambaro R | 2005 | Anti- eaneer Res2005，25，5： | 1 |
| 6 | Biosimilar ep oetin alpha is as effective as originator epoetin-al- pha plus liposomal iron ($ideral(R)), vitamin Bl2 and folates in patients with refractory anemia: A retro spective real life approach显示文摘 | Giordano G Mondello P Tambaro R | 2015 | Mol Clin Oncol2015，3，4： | 1 |
| 7 | A phase Ⅱ random- ized Bayesian study of very low dose subcutaneous decitabine ad- ministered daily or weekly times three in patients with lower risk myelodysplastic syndrome (MDS) 显示文摘 | Garcia-Manero G Couriel D Tambaro F | 2009 | Blood2009，114，： | 1 |
| 8 | Safety of cis- platin after severe hypersensitivity reactions to carboplatin in pa- tients with recurrent ovarian carcinoma 显示文摘 | OTTAIANO A TAMBARO R GREGGI S | 2003 | Anticancer Res2003，23，4： | 1 |
| 9 | Activity of chemotherapy in mucinous epithelial ovarian cancer:a retrospective study显示文摘 | Pisano C Greggi S Tambaro R | 2005 | Anticancer Res2005，25，5： | 1 |
| 10 | Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer:a dose-escalation study显示文摘 | Caravatta L Picardi V Tambaro R | | 0，，： | 1 |
| 11 | Neoadjuvant ac- celerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: a dose- escalation study显示文摘 | Caravatta L Picardi V Tambaro R | 2012 | Am J Clin Oneol2012，35，： | 1 |
| 12 | Phase Ⅱ trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myeJodysplastic syndrome显示文摘 | Gareia-Manero G Tambaro FP Bekele NB | 2012 | J Clin Oncol2012，30，18： | 1 |
| 13 | Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in lo- cally advanced rectal cancer: a dose-escalation study显示文摘 | Caravatta L Picardi V Tambaro R | 2012 | Am J Clin Oncol2012，35，5： | 1 |
| 14 | Activity of chemotherapy in mucinous epithelial ovarian cancer:A retrospective study显示文摘 | Pisano C Greggi S Tambaro R | 2005 | Anticancer Res2005，25，5： | 1 |
| 15 | Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays 显示文摘 | Tambaro S Ruiu S Dessi C | 2005 | J Pharmacol Exp Ther2005，312，2： | 1 |
| 16 | Histone acetyltransferase inhibitors and preclinical studies显示文摘 | Manzo F Tambaro FP Mai A | 2009 | Expert Opin Ther Pat2009，19，6： | 1 |
| 17 | The role of chemotherapy in locally advanced,metastatic and recurrent cervical cancer显示文摘 | Tambaro R Scambia G Di Maio M | 2004 | Crit Rev Oncol Hematol2004，52，1： | 1 |
| 18 | Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in lo eally advanced rectal cancer: a dose-escalation study显示文摘 | Caravatta L Picardi V Tambaro R | 2012 | Am J Clin On- col2012，35，5： | 1 |
| 19 | The role of chemotherapy in locally advanced,metastatic and recurrent cervical cancer显示文摘 | TAMBARO R SCAMBIA G Di Maio M | 2004 | Crit Rev Oncol Hematol2004，52，1： | 1 |
| 20 | Neoadjuvant accelerated concomitant boost radiotherapy and multidmg chemotherapy in locally advanced rectal cancer:a dose-escalation study显示文摘 | Caravatta L Picardi V Tambaro R | 2012 | Am J Clin Oncol2012，35，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员